Connect your AI

UroGen Pharma URGN Payments for finance leases

Payments for finance leases at other companies

ImmunityBio, Inc.IBRX

$13K—

LQD

Liquidia CorporationLQDA

$0-100%

Other financials

Income statement

Revenue$51.0M+152%

Gross profit$11.6M—

Operating income-$22.8M—

Net income-$23.6M+46.2%

EPS (diluted)-$1.17—

Balance sheet

Cash & equivalents$110.0M+5.7%

Total debt$197.1M+56.0%

Total equity-$124.3M-167%

Total assets$253.7M+2.5%

Cash flow

Operating cash flow-$45.3M-7.8%

CapEx$54.0K+22.7%

Free cash flow-$45.4M-7.8%

Valuation

Market cap$1.73B+71.7%

Enterprise value$1.81B+80.9%

P/S12.3×+1.3×

Profitability

Gross margin89.7%—

Operating margin-329.7%—

Net margin-94.8%-25.6pp

FCF margin-118.2%+1.3pp

Returns & leverage

Return on equity-211.6%—

Debt / equity4.8×—

Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeasePrincipalPayments.

The official record: UroGen Pharma’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's payments for finance leases.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is UroGen Pharma's payments for finance leases?: UroGen Pharma (URGN) reported payments for finance leases of $463.75K in Q4 2025.
What does payments for finance leases mean?: Principal payments on finance lease obligations, reducing the lease liability on the balance sheet.